思合基因作为反义寡核酸（ASO）生物技术公司，我们突破了ASO新药设计的" 卡脖子"瓶颈，聚焦底层技术，建立了关键专利壁垒。公司自主开发的三大核心技术 平台，构建了完整的ASO药物研发体系。公司已入选国家高新技术企业、专精特新中 小企业。我们聚焦中枢神经系统、眼科、肝脏疾病、感染等领域。其中，核心肝脏疾 病管线已进入IND申报准备阶段，2025年研发取得重大突破。我们与国内多家科研机 构合作，提供从靶点筛选到IND申报的一站式研发服务。携手创新，攻克疾病！

 As an antisense oligonucleic acid (ASO) biotechnology company, we have  broken through the bottleneck of ASO's new drug design, focused on the underlying  technology, and established key patent barriers. The three core technology platforms  independently developed by the company have built a complete ASO drug research  and development system. The company has been selected as a national high-tech  enterprise, specialized and new small and medium-sized enterprises.We focus  on the central nervous system, ophthalmology, liver diseases, infections and  more.Among them, the core liver disease pipeline has entered the preparation stage  for IND application, and a major breakthrough in research and development will be  made in 2025.We cooperate with a number of domestic scientific research institutions to provide one-stop R&D services from target screening to IND filing. Innovate together to overcome disease!

地址：北京市海淀区永腾北路9号院贝伦产业园15号楼

Building 15, Beilun Industrial Park, 9 North Yongteng Road,

Haidian District Beijing, Beijing, China